Vantage Investment Partners LLC Buys 167,282 Shares of Zoetis Inc. $ZTS

Vantage Investment Partners LLC bought a new position in Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 167,282 shares of the company’s stock, valued at approximately $11,681,000.

Other large investors have also recently made changes to their positions in the company. Flossbach Von Storch SE bought a new position in Zoetis during the 2nd quarter valued at about $302,601,000. BlackRock Inc. lifted its stake in Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. purchased a new position in shares of Zoetis during the first quarter valued at approximately $286,660,000. Southpoint Capital Advisors LP boosted its position in shares of Zoetis by 340.0% during the first quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock valued at $260,062,000 after buying an additional 1,700,000 shares during the period. Finally, Carmignac Gestion purchased a new position in shares of Zoetis during the second quarter valued at approximately $113,230,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.7%

ZTS stock opened at $77.67 on Thursday. The company has a market capitalization of $32.10 billion, a PE ratio of 12.80, a P/E/G ratio of 1.20 and a beta of 0.74. Zoetis Inc. has a 12 month low of $68.77 and a 12 month high of $146.11. The firm’s 50-day moving average is $74.91 and its 200 day moving average is $94.11. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter last year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is 34.93%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Cantor Fitzgerald set a $94.00 target price on Zoetis in a research note on Tuesday, August 25th. Morgan Stanley set a $85.00 price target on Zoetis in a research note on Friday, August 7th. JPMorgan Chase & Co. dropped their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Barclays dropped their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Zoetis in a research report on Wednesday, September 9th. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $98.40.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.